Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for Section 101
JMLS IP Conference (Report 2): Patent eligibility, anti-anti suits and the era of unpredictability JMLS IP Conference (Report 2): Patent eligibility, anti-anti suits and the era of unpredictability Reviewed by Annsley Merelle Ward on Friday, November 22, 2019 Rating: 5
Fordham 27 (Report 4): Government Leaders’ Perspectives on IP Fordham 27 (Report 4): Government Leaders’ Perspectives on IP Reviewed by Annsley Merelle Ward on Friday, April 26, 2019 Rating: 5
Fordham 27 (Report 2): IP - Past, Present & Future Fordham 27 (Report 2): IP - Past, Present & Future Reviewed by Annsley Merelle Ward on Thursday, April 25, 2019 Rating: 5
Judge sounds alarm of weakened US patent system, while industry groups start amending Section 101 Judge sounds alarm of weakened US patent system, while industry groups start amending Section 101 Reviewed by Annsley Merelle Ward on Monday, May 22, 2017 Rating: 5
Bad and Good News for Bio-Pharmaceutical Patenting in the United States Bad and Good News for Bio-Pharmaceutical Patenting in the United States Reviewed by Mike Mireles on Wednesday, August 17, 2016 Rating: 5
Curiouser and Curiouser? More details on Alice v CLS Bank decision of SCOTUS Curiouser and Curiouser? More details on Alice v CLS Bank decision of SCOTUS Reviewed by Darren Smyth on Tuesday, June 24, 2014 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.